Table 4.
Detailed data of the 14 cases with discrepant findings between antigen test and real-time RT-PCR.
| Case number | Symptoms | Days from thesymptom onset to sample collection |
Ct value |
Notes | |
|---|---|---|---|---|---|
| N1a | N2a | ||||
| 1 | + | 7 | ND | 34 | |
| 2 | + | 3 | ND | 40 | |
| 3 | + | 6 | 31 | 24 | |
| 4 | + | 6 | 35 | 30 | Preceding favipiravir administration |
| 5 | + | 4 | 38 | 35 | |
| 6 | – | NA | ND | 36 | |
| 7 | – | NA | ND | 39 | |
| 8 | – | NA | ND | 37 | |
| 9 | – | NA | 37 | 31 | |
| 10 | – | NA | ND | 38 | |
| 11 | + | 7 | 36 | 30 | |
| 12 | – | NA | 35 | 30 | |
| 13 | – | NA | 41 | 39 | |
| 14 | – | NA | ND | 34 | |
Ct, cycle threshold; NA, not available; ND, not detected.
a
Real-time reverse transcription polymerase chain reaction examinations of SARS-CoV-2 developed by the National Institute of Infectious Diseases, Japan [6].